We are live on ! Find out more
GILD icon

Gilead Sciences

982 hedge funds and large institutions have $96.8B invested in Gilead Sciences in 2013 Q3 according to their latest regulatory filings, with 88 funds opening new positions, 337 increasing their positions, 440 reducing their positions, and 46 closing their positions.

New
Increased
Maintained
Reduced
Closed

91% more first-time investments, than exits

New positions opened: 88 | Existing positions closed: 46

39% more funds holding in top 10

Funds holding in top 10: 82114 (+32)

20% more capital invested

Capital invested by funds: $80.8B → $96.8B (+$16B)

4% more funds holding

Funds holding: 948982 (+34)

23% less repeat investments, than reductions

Existing positions increased: 337 | Existing positions reduced: 440

67% less call options, than puts

Call options by funds: $785M | Put options by funds: $2.37B

Holders
982
Holders Change
+34
Holders Change %
+3.59%
% of All Funds
31.83%
Holding in Top 10
114
Holding in Top 10 Change
+32
Holding in Top 10 Change %
+39.02%
% of All Funds
3.7%
New
88
Increased
337
Reduced
440
Closed
46
Calls
$785M
Puts
$2.37B
Net Calls
-$1.58B
Net Calls Change
-$165M
Name Holding Trade Value Shares
Change
Change in
Stake
Norges Bank
26
Norges Bank
Norway
$706M -$34.8M -582,434 -5%
Geode Capital Management
27
Geode Capital Management
Massachusetts
$697M +$22.7M +380,141 +4%
Goldman Sachs
28
Goldman Sachs
New York
$651M +$153M +2,567,407 +33%
CGT
29
Capital Guardian Trust
California
$643M -$122M -2,049,307 -17%
Capital International Investors
30
Capital International Investors
California
$634M -$15.9M -266,600 -3%
Winslow Capital Management
31
Winslow Capital Management
Minnesota
$607M -$27.3M -456,166 -5%
Edgewood Management
32
Edgewood Management
Connecticut
$563M +$61.9M +1,035,360 +13%
Bank of America
33
Bank of America
North Carolina
$560M -$396M -6,619,802 -43%
BA
34
BlackRock Advisors
Delaware
$515M -$8.19M -137,098 -2%
Massachusetts Financial Services
35
Massachusetts Financial Services
Massachusetts
$490M +$91M +1,522,873 +24%
O
36
OppenheimerFunds
New York
$469M +$99.7M +1,668,776 +29%
AllianceBernstein
37
AllianceBernstein
Tennessee
$456M +$385K +6,436 +0.1%
VOYA Investment Management
38
VOYA Investment Management
Georgia
$420M +$7.36M +123,192 +2%
Legal & General Group
39
Legal & General Group
United Kingdom
$412M -$1.09M -18,259 -0.3%
WRF
40
Waddell & Reed Financial
Kansas
$407M -$67.1M -1,123,062 -15%
EVM
41
Eaton Vance Management
Massachusetts
$403M -$23M -385,486 -6%
GE
42
General Electric
Ohio
$360M +$4.91M +82,177 +1%
MAA
43
Managed Account Advisors
New Jersey
$335M -$13.2M -221,358 -4%
New York State Common Retirement Fund
44
New York State Common Retirement Fund
New York
$326M -$10.4M -174,291 -3%
PHS
45
PFM Health Sciences
California
$323M -$109M -1,823,537 -26%
CCI
46
Columbus Circle Investors
$322M -$43.9M -734,697 -13%
Morgan Stanley
47
Morgan Stanley
New York
$302M -$17.3M -289,834 -6%
O
48
OrbiMed
New York
$300M -$2.63M -44,000 -0.9%
CS
49
Credit Suisse
Switzerland
$297M -$127M -2,122,674 -31%
FAM
50
Fred Alger Management
New York
$284M +$16.1M +269,657 +6%

GILD Hedge Fund Activity: Q3 2013 in Review

982 of the 3,085 institutional investors tracked by Wall St. Rank reported a position in Gilead Sciences (GILD) for Q3 2013, worth a combined $96.8B — up 20% from $80.8B a quarter earlier.

Buyers outnumbered sellers: 88 funds opened new GILD positions and 46 closed out — a net gain of 42 holders — while 337 added to existing stakes and 440 trimmed.

The largest buyer was Montag & Caldwell, opening a new position worth an estimated $230M. The largest seller was Capital World Investors, cutting an estimated $397M.

  • 982 institutional investors held Gilead Sciences (GILD) as of Q3 2013, up from 948 in Q2 2013.
  • Funds reported $96.8B of Gilead Sciences stock for Q3 2013, up 20% quarter-over-quarter.
  • 88 funds opened new Gilead Sciences positions in Q3 2013 and 46 closed out, a net change of +42 holders.
  • The largest Gilead Sciences buyer in Q3 2013 was Montag & Caldwell, an estimated $230M added.
  • The largest Gilead Sciences seller in Q3 2013 was Capital World Investors, an estimated $397M sold.

Based on aggregated 13F filings for Q3 2013.